HIIFS
VRTX icon

Harel Insurance Investments & Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
3,837
+823
+27% +$365K 0.01% 173
2026
Q1 		$1.35M Buy
3,014
+578
+24% +$270K 0.01% 156
2025
Q4 		$1.1M Buy
2,436
+379
+18% +$163K 0.01% 171
2025
Q3 		$806K Buy
2,057
+787
+62% +$329K 0.01% 204
2025
Q2 		$565K Buy
1,270
+504
+66% +$232K 0.01% 216
2025
Q1 		$371K Sell
766
-140
-15% -$65.2K ﹤0.01% 234
2024
Q4 		$365K Sell
906
-4,259
-82% -$1.97M 0.01% 170
2024
Q3 		$2.4M Sell
5,165
-6,777
-57% -$3.26M 0.04% 119
2024
Q2 		$5.63M Buy
11,942
+432
+4% +$188K 0.11% 72
2024
Q1 		$4.81M Buy
11,510
+1,412
+14% +$597K 0.09% 77
2023
Q4 		$4.12M Buy
10,098
+4,758
+89% +$1.76M 0.07% 95
2023
Q3 		$1.88M Sell
5,340
-4,918
-48% -$1.72M 0.04% 134
2023
Q2 		$3.57M Buy
10,258
+7,023
+217% +$2.37M 0.09% 72
2023
Q1 		$1.01M Buy
3,235
+669
+26% +$201K 0.02% 173
2022
Q4 		$740K Sell
2,566
-136
-5% -$41.4K 0.02% 174
2022
Q3 		$791K Buy
2,702
+2,301
+574% +$662K 0.02% 175
2022
Q2 		$113K Buy
401
+52
+15% +$13.9K ﹤0.01% 391
2022
Q1 		$91K Buy
+349
New +$82.8K ﹤0.01% 451
2021
Q3 		– Sell
-578
Closed -$380K – 811
2021
Q2 		$380K Sell
578
-291
-33% -$60.9K 0.01% 510
2021
Q1 		$624K Sell
869
-3,099
-78% -$681K 0.01% 468
2020
Q4 		$3.02M Buy
3,968
+604
+18% +$139K 0.07% 133
2020
Q3 		$915K Buy
3,364
+2,664
+381% +$735K 0.03% 132
2020
Q2 		$203K Buy
+700
New +$190K 0.01% 249
2017
Q1 		– Sell
-48
Closed -$4K – 487
2016
Q4 		$4K Sell
48
-490
-91% -$39.9K ﹤0.01% 347
2016
Q3 		$47K Sell
538
-132
-20% -$12.5K 0.01% 228
2016
Q2 		$58K Sell
670
-160
-19% -$13.8K 0.01% 322
2016
Q1 		$66K Sell
830
-453
-35% -$41K 0.01% 186
2015
Q4 		$161K Buy
+1,283
New +$155K 0.02% 116

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Harel Insurance Investments & Financial Services's VRTX Position: Q2 2026 in Review

Harel Insurance Investments & Financial Services increased its Vertex Pharmaceuticals (VRTX) stake by 27% in Q2 2026, buying an estimated $365K and bringing the position to 3,837 shares worth $1.91M. The position accounts for 0.01% of the portfolio, ranked #173.

Harel Insurance Investments & Financial Services first reported a position in VRTX in Q4 2015 and has held it in 28 quarters since. The position peaked at $5.63M in Q2 2024. 1,296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Harel Insurance Investments & Financial Services held 3,837 shares of Vertex Pharmaceuticals worth $1.91M as of Q2 2026.
  • Harel Insurance Investments & Financial Services bought 823 Vertex Pharmaceuticals shares in Q2 2026, an estimated $365K.
  • Vertex Pharmaceuticals made up 0.01% of Harel Insurance Investments & Financial Services's portfolio in Q2 2026, its #173 holding.
  • Harel Insurance Investments & Financial Services first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 28 quarters since.
  • Harel Insurance Investments & Financial Services's Vertex Pharmaceuticals position peaked at $5.63M in Q2 2024.
  • 1,296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q2 2026, filed 29 Jul 2026.